Jennifer Jimenez
Acute Care · Indianapolis, INNPI 1598251951
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $2,250 of the $3,102 with a category attached, or 72.5%. AbbVie accounts for 73.4% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2023 at $2,293 and has fallen 79.3% since, to $474 in 2025.
Across 22 payments — averaging $141.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Teva Pharmaceuticals USA, Inc.$327
- Neurocrine Biosciences, Inc.$164
- Corium, LLC$130
- E.r. Squibb & Sons, L.L.C.$106
- Almatica Pharma LLC$42
- plus $54 from 2 others
What the payments were for
- Speaking & faculty fees$2,25073%
- Food & beverage$56418%
- Education$2889%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 4 | $2,278 |
| Teva Pharmaceuticals USA, Inc. | 6 | $327 |
| Neurocrine Biosciences, Inc. | 5 | $164 |
| Corium, LLC | 1 | $130 |
| E.r. Squibb & Sons, L.L.C. | 1 | $106 |
| Almatica Pharma LLC | 3 | $42 |
| Atricure, Inc. | 1 | $41 |
| Lundbeck LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,102 in reported general payments places this provider in the 85th percentile of 240 acute care providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 17 | $13,293 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 21 | $816 |
| Memantine Hcl | 47 | $442 |
| Pantoprazole Sodium | 19 | $97 |
| Atorvastatin Calcium | 16 | $77 |
| Amlodipine Besylate | 24 | $70 |
| Carvedilol | 11 | $59 |
| Prednisone | 12 | $21 |
Paid to pharmacies, not to this prescriber.
Other acute care in Indianapolis
- Lauren ArmingtonIndianapolis$7K
- Ashley HillIndianapolis$7K
- Rebecca DavidhizarIndianapolis$3K
- Jennifer DimitroffIndianapolis$3K
- Lisa SimsIndianapolis$3K
- Kylie BeutlerIndianapolis$2K
- Alexis SmithIndianapolis$2K
- Katelyn PorterIndianapolis$2K
- Rebecca CobbIndianapolis$2K
- Jennifer BrowerIndianapolis$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.